The knowledge of SGLT-2 inhibitors’ effectiveness results, nowadays, in the increasing use of these pharmacological agents as monotherapy or associated with other antidiabetic drugs both in patients with T2D and with HF (Table 2). This evidence concerns the gene SLC5A2 and hydrops fetalis.